Biogen Cost increased by 0.0% to $227.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 65.9%, from $668.70M to $227.80M. Over 5 years (FY 2020 to FY 2025), Cost shows a downward trend with a -28.7% CAGR.
Changes in this cost basis reflect the bank's strategic decision to increase or decrease its direct equity investment holdings.
This represents the original cost basis of equity securities that are measured at fair value through net income. It prov...
Standard accounting disclosure for equity investments under current fair value accounting standards.
other_equity_securities_fv_ni_cost| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.17B | $1.17B | $1.17B | $1.14B | $1.13B | $1.13B | $1.09B | $1.00B | $993.30M | $979.90M | $928.40M | $800.20M | $734.30M | $668.70M | $668.70M | $668.70M | $227.80M | $227.70M | $227.80M |
| QoQ Change | — | -0.2% | +0.0% | -2.6% | -0.3% | +0.0% | -4.0% | -8.1% | -0.8% | -1.3% | -5.3% | -13.8% | -8.2% | -8.9% | +0.0% | +0.0% | -65.9% | -0.0% | +0.0% |
| YoY Change | — | — | — | — | -3.0% | -2.8% | -6.7% | -12.0% | -12.4% | -13.6% | -14.7% | -20.1% | -26.1% | -31.8% | -28.0% | -16.4% | -69.0% | -65.9% | -65.9% |